La Jolla Pharmaceutical Company Announces Final Dosing In Phase 2 Clinical Trial Of GCS-100 In Chronic Kidney Disease

Published: Feb 21, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”), a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases today announced that it has completed dosing of its Phase 2 clinical trial of GCS-100 for the treatment of chronic kidney disease (“CKD”) and has collected the final data for evaluation of the primary endpoint. The primary efficacy endpoint is the change in estimated glomerular filtration rate (“eGFR”) from baseline to the average at Day 50 and 57 in each GCS-100 dose group compared to placebo. The primary endpoint will be reached if the difference in eGFR between either GCS-100 dose group and placebo has a significance of less than 10% (p-value of <0.1).

Help employers find you! Check out all the jobs and post your resume.

Back to news